An accelerated-phase CML patient with e19a2 junction of BCR/ABL gene -: the first case of transplanted CML with micro bcr

被引：11
|
作者：
Polák, J
Koza, V
Cetkovsky, P
Haskovec, C
机构：
[1] Inst Hematol & Blood Transfus, Dept Mol Genet, CR-12820 Prague 2, Czech Republic
[2] Fac Hosp, Dept Hematooncol, Plzen, Czech Republic
来源：
BONE MARROW TRANSPLANTATION | 2000年 / 25卷 / 10期
关键词：
D O I：
10.1038/sj.bmt.1702412
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：1109 / 1110
页数：2
相关论文
共 50 条
  • [41] Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase
    Moravcová, J
    Zmeková, V
    Klamová, H
    Voglová, J
    Faber, E
    Michalová, K
    Rabasová, J
    Jarosová, M
    LEUKEMIA RESEARCH, 2004, 28 (04) : 415 - 419
  • [42] Quantitative RT-PCR of Wilms tumor gene transcripts (WT1) for the molecular monitoring of patients with accelerated phase bcr/abl plus CML
    Na, IK
    Kreuzer, KA
    Lupberger, J
    Dörken, B
    le Coutre, P
    LEUKEMIA RESEARCH, 2005, 29 (03) : 343 - 345
  • [43] e19a2 BCR-ABL fusion transcript in typical chronic myeloid leukaemia: a report of two cases
    Mondal, B. C.
    Majumdar, S.
    Dasgupta, U. B.
    Chaudhuri, U.
    Chakrabarti, P.
    Bhattacharyya, S.
    JOURNAL OF CLINICAL PATHOLOGY, 2006, 59 (10) : 1102 - 1103
  • [44] AN ATYPICAL JUNCTION OF BCR-ABL GENE AS MOLECULAR MARKER FOR QUANTITATIVE MONITORING OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML)
    Jurcek, T.
    Dvorakova, D.
    Pospisilova, J.
    Ohlidalova, D.
    Mayer, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 433 - 433
  • [45] Effectiveness of First and Second Line Nilotinib in Chronic Myeloid Leukemia (CML) Patients with Atypical e1a2 BCR-ABL Transcripts
    Gui, Xiaomin
    Pan, Jinlan
    Qiu, Huiying
    Cen, Jiannong
    Xue, Yongquan
    Chen, Suning
    He, Jun
    Shen, Hongjie
    Yao, Li
    Zhang, Jun
    Wu, Yafang
    Wu Depei
    BLOOD, 2014, 124 (21)
  • [46] Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report
    Massimino, Michele
    Stella, Stefania
    Tirro, Elena
    Consoli, Maria Letizia
    Pennisi, Maria Stella
    Puma, Adriana
    Vitale, Silvia Rita
    Romano, Chiara
    Zammit, Valentina
    Stagno, Fabio
    Di Raimondo, Francesco
    Manzella, Livia
    ANTICANCER RESEARCH, 2019, 39 (07) : 3949 - 3954
  • [47] Detection and Clinical Implications of a Novel BCR-ABL1 E12A2 Insertion/Deletion in a CML Patient Expressing the E13A2 Isoform
    Stella, Stefania
    Massimino, Michele
    Tirro, Elena
    Vitale, Silvia Rita
    Accurso, Vincenzo
    Puma, Adriana
    Pennisi, Maria Stella
    Di Gregorio, Sandra
    Romano, Chiara
    Di Raimondo, Francesco
    Siragusa, Sergio
    Manzella, Livia
    ANTICANCER RESEARCH, 2019, 39 (12) : 6965 - 6971
  • [48] Molecular Response of e19a2 BCR-ABL1 Chronic Myeloid Leukemia With Double Philadelphia Chromosome to Dasatinib
    Ikeda, Kazuhiko
    Harada-Shirado, Kayo
    Matsumoto, Hayato
    Noji, Hideyoshi
    Ogawa, Kazuei
    Takeishi, Yasuchika
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (14) : E130 - E133
  • [49] First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts
    Andrikovics, Hajnalka
    Nahajevszky, Sarolta
    Szilvasi, Aniko
    Bors, Andras
    Adam, Emma
    Kozma, Andras
    Kajtar, Bela
    Barta, Aniko
    Poros, Anna
    Tordai, Attila
    HEMATOLOGICAL ONCOLOGY, 2007, 25 (03) : 143 - 147
  • [50] Chronic Myeloid Leukemia with e19a2 BCR-ABL1 Transcripts and Marked Thrombocytosis: The Role of Molecular Monitoring
    Langabeer, Stephen E.
    McCarron, Sarah L.
    Kelly, Johanna
    Krawczyk, Janusz
    McPherson, Suzanne
    Perera, Kanthi
    Murphy, Philip T.
    CASE REPORTS IN HEMATOLOGY, 2012, 2012
12345